COVID-19 Clinical Trial
Official title:
Evaluation of the Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores of Patients With Severe COVID 19 Pneumonia in Intensive Care.
Coronavirus Disease 19 (COVID-19) pandemic has become a global health problem in a short time
due to high infection rate and increasing mortality. Since it is not possible to perform
thorax computed tomography (CT) and transfer of patients with COVID-19 pneumonia who are
followed up in intensive care, diagnosis and follow-up by lung ultrasound (LUS) is a great
advantage nowadays.The investigators aimed to evaluate the correlation between thoracic CT
score and LUS score and to determine its relationship with mortality.
Patients who were admitted to intensive care with the diagnosis of COVID-19 pneumonia, who
had an initial thorax CT examination and who underwent LUS during admission to the intensive
care unit were included in the study. The demographic characteristics, clinical parameters,
prognosis, thorax CT and LUS scores of the patients were recorded prospectively. The
characteristics of the survived patients and the patients who died were compared.
Thorax CT scoring was performed by an experienced radiologist, while LUS scoring was
performed an experienced anaesthesia and reanimation specialist. The demographic
characteristics, clinical parameters, prognosis, thorax CT and LUS scores of the patients
were recorded prospectively. The correlation between thorax CT score and LUS score was
evaluated.Lung ultrasound score (LUSS):
LUS was performed by an intensive care specialist with experience in this field using a 2- to
5-MHz transducer (Esaote MyLabSeven, Getz Healthcare Malaysia). The transducer was covered
with a probe cover, and the transducer and ultrasound device were cleaned with disinfectant
wipes after each use. LUS examinations were performed at the bedside, in the supine position,
and twelve-zone examinations were performed. Each hemithorax is separated into 6 quadrants:
anterior, lateral, and posterior zones (separated by the anterior and posterior axillary
lines) each divided in upper and lower portion (Figure 1). Each zone was scored according to
the LUS pattern as follows: the presence of lung sliding with A-lines or fewer than two
isolated B-lines, scored 0; when multiple well-defined B-lines presented, scored 1; the
presence of multiple coalescent B-lines, scored 2; and when presented with a tissue pattern
characterized by dynamic air bronchograms (lung consolidation), scored 3. The worst
ultrasound pattern observed in each zone was recorded and used to calculate the sum of the
scores (total score = 36).
CT Technique and Image Interpretation The thorax CT scans in the study were obtained using
the low dose protocol of our hospital with a 128-slice multi-detector CT scanner (Optima;
General Electric Healthcare, Wisconsin, USA). All CT scans were performed during a single
breath-hold without contrast administration.
As in the ultrasound evaluation, each lung was divided into anterior, lateral and posterior
quadrants based on the anterior and posterior axillary lines, and then each quadrant was
divided into upper and lower sections. Each quadrant was scored between 0-3. It was scored 0
when there was no parenchymal involvement, 1score when the parenchymal involvement rate was
between 0 and 33%, 2 score when it was between 33% and 66%, and 3score when it was above 66%.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|